Recent return profile and business snapshot

Corcept Therapeutics (CORT) has drawn fresh attention after a strong recent share price run, with the stock up 1.1% over the past day, 2.4% over the past week and 32.4% over the past month.

Over the past 3 months, the stock is up 71.4%, while the past year shows a total return decline of 21.6%. Longer horizons look different, with total returns of 143.4% over 3 years and 175.4% over 5 years.

The company, headquartered in Redwood City, California, focuses on discovering and developing medications targeting severe endocrinologic, oncologic, metabolic and neurologic disorders. Its commercial portfolio and pipeline provide important context for assessing these recent share price moves.

At a share price of $59.69, Corcept Therapeutics sits on strong recent momentum, with a 30 day share price return of 32.4% and a 90 day share price return of 71.4%, contrasting with a 1 year total shareholder return that declined 21.6%. Over longer periods of 3 and 5 years, total shareholder returns have been strongly positive.

If this kind of sharp rebound has you looking for more opportunities in healthcare, it could be worth scanning a wider field using our screener for 33 healthcare AI stocks

After such a sharp rebound and with the stock trading below some implied value estimates, the key question now is simple: is Corcept Therapeutics still undervalued or is the market already pricing in future growth?

Most Popular Narrative: 6% Undervalued

Corcept Therapeutics last closed at $59.69, while the most followed narrative points to a fair value of $63.53 based on a discounted cash flow approach.

Ottima azienda solida finanziariamente senza debiti a lungo e breve termine. Il FcF tende a diminuire nel tempo mentre aumentano i compensi per i vari membri del board che hanno uno skill in the game moderato. Calcolando il DCF , con un approccio un po ottimistico, quindi , valutando la crescita del fcf al 10% per i primi 5 annni e al 7% dal 6 al 10, calcolando un tasso di sconto al 12% e una crescita del 3% annuo (valore in linea con l aumento medio del pil Usa) il mio fair value è di circa 33 euro al quale sottraggo un MoS del 30% , quindi ho impostato l acquisto a 23 euro circa. Anche il P/E di 31 mi da un' indicazione del genere, Quindi attualmente è sopravvalutata.

Read the Read the complete narrative.

Want to see what sits behind that fair value and the current undervaluation tag? The narrative leans heavily on free cash flow trends, margin resilience and a confident discount rate to justify its view. The tension between falling reported margins and strong projected profitability is front and center, and the full narrative sets out how that gap is bridged.

Result: Fair Value of $63.53 (UNDERVALUED)

However, you still need to watch for clinical or regulatory setbacks in the pipeline, as well as any sustained pressure on free cash flow that challenges the DCF assumptions.

Another View: Earnings Multiple Sends A Different Signal

While the SWS DCF workup points to Corcept Therapeutics trading 28.6% below an estimated future cash flow value, the current P/E of 137.3x tells a very different story. It is far above the fair ratio of 36.8x, the US pharmaceuticals average of 14.8x and the 22.5x peer average, which suggests a lot has to go right to justify today’s price. So is this a mispricing, or are earnings expectations simply that high?

Next Steps

After reading this, do you feel the story is more promising or more concerning at the moment? Consider the information while it is still fresh in your mind and shape your own takeaway by reviewing the balance of 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Corcept has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted stock ideas that you can start researching today.

• Target growth at a discount by scanning 53 high quality undervalued stocks that pair solid fundamentals with prices that sit below many investors’ expectations.
• Seek reliability in rough markets by checking 66 resilient stocks with low risk scores built around companies with more resilient risk profiles.
• Get ahead of the crowd by reviewing our screener containing 20 high quality undiscovered gems before they land on every other investor’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.